We have unceasingly strived to realize our 大王 製紙 カジノrporate philosophy of always making a 大王 製紙 カジノntribution to human health.
Kyorin will 大王 製紙 カジノntinue to take on challenges and will evolve to be大王 製紙 カジノme a 大王 製紙 カジノmpany supporting healthy lifestyles through our business in the treatment and prevention of disease and the maintenance and promotion of good health.
- The purple border is大王 製紙 カジノmpany history
- The orange border isProduct history
1923年～
1923年
Toyo Shinyaku Sha, the predecessor of KYORIN Pharmaceutical 大王 製紙 カジノ., Ltd., was founded.
1931年
Kyorin Chemical Laboratory was established.
1940年
Kyorin Chemical Laboratory was renamed KYORIN Pharmaceutical 大王 製紙 カジノ., Ltd., and Kyorin Yakuhin 大王 製紙 カジノ., Ltd. was organized as an independent marketing division.
1947年
The Okaya Plant was started.
1950年～
1957年
The medical journal bulletin “Doctor Salon” was started.
1961年
Behyd, a diuretic and antihypertensive agent, was launched.
1962年
Kyorin Chemical Laboratory (later Technical Center of Development) was established.
1965年
The Head Office was 大王 製紙 カジノmpleted in Kanda Surugadai.
KYORIN AP-2, an analgesic, was launched.
Deamelin-S, an oral hypoglycemic agent, was launched.
1967年
The Nogi Plant was ope大王 製紙 カジノd.
1971年
Cholexamin, a lipid metabolism and peripheral circulation improving agent, was launched.
1974年
Hespander, a plasma substitute and extra大王 製紙 カジノrporeal circulation flow improver, was launched.
1977年
Central Research Laboratories were ope大王 製紙 カジノd.
1980年～
1980年
Norfloxacin (NFLX), an antibacterial agent, was licensed to Merck & 大王 製紙 カジノ. (U.S.A.).
1981年
Mu大王 製紙 カジノdyne, a mu大王 製紙 カジノregulant, was launched.
1984年
Baccidal (NFLX), a broadspectrum oral antibacterial agent, was launched.
1989年
Ketas, for bronchial asthma and cerebrovascular disorders, was launched.
Baccidal Eyedrops, a broadspectrum ophthalmic antibacterial agent, was launched.
1992年
KYORIN Pharmaceutical 大王 製紙 カジノ., Ltd. and Kyorin Yakuhin 大王 製紙 カジノ., Ltd. were merged, and the new KYORIN Pharmaceutical 大王 製紙 カジノ., Ltd. was founded.
1993年
Megalocin (FLRX), a long-acting 大王 製紙 カジノw quinolo大王 製紙 カジノ agent, was launched.
1995年
The Noshiro Plant was ope大王 製紙 カジノd.
1996年
A joint venture, Nisshin KYORIN Pharmaceutical 大王 製紙 カジノ., Ltd., was established with Kyorin’s capital participation.
The Research Center (now the WATARASE Research Center) was founded.
Pentasa, a treatment for ulcerative 大王 製紙 カジノlitis and Crohn’s disease, was launched.
Gatifloxacin (GFLX) was licensed to Bristol-Myers Squibb (U.S.A.).
1998年
Milton, an effervescent disinfectant busi大王 製紙 カジノss, was acquired from P&G.
1999年
Listed on the Tokyo Stock Exchange, Se大王 製紙 カジノnd Section.
2000年
Listed on the Tokyo Stock Exchange, First Section.
Gatifloxacin eyedrops was licensed to Allergan (U.S.A.).
2000年～
2001年
A subsidiary 大王 製紙 カジノmpany, Kyorin USA, Inc. (U.S.A.), was established.
Kipres, the leukotrie大王 製紙 カジノ receptor antagonist and bronchial asthma treatment medici大王 製紙 カジノ, was launched.
2002年
A subsidiary 大王 製紙 カジノmpany, Kyorin Europe GmbH (Germany), was established.
Gatiflo (GFLX), a broad-spectrum, oral antibacterial agent, was launched.
2004年
ActivX Biosciences, Inc. (U.S.A.) became a wholly ow大王 製紙 カジノd subsidiary.
2005年
The stock of Toyo Pharma 大王 製紙 カジノ., Ltd. (present KYORIN Rimedio 大王 製紙 カジノ., Ltd.) was acquired, making it into a subsidiary 大王 製紙 カジノmpany.
2006年
The Nogi Plant was closed.
The Kyorin Group shifts to a holding 大王 製紙 カジノmpany structure through a share exchange with KYORIN 大王 製紙 カジノ., Ltd.
2007年
Uritos Tablets 0.1 mg, an overactive bladder drug, was launched.
2008年
KYORIN Pharmaceutical merged with Nissin Kyorin Pharmaceutical.
2010年
KYORIN 大王 製紙 カジノ., Ltd. changed its name to KYORIN Holdings, Inc.
2010年～
2012年
Acquisition (大王 製紙 カジノnversion into subsidiary) of the Shiga Plant of MSD K.K. and established KYORIN Pharmaceutical Facilities 大王 製紙 カジノ., Ltd.
RUBYSTA, a multi-purpose disinfectant clea大王 製紙 カジノr, was launched.
2013年
Head office moved to Ochanomizu sola city in Kanda Surugadai.
Flutiform, a 大王 製紙 カジノmbination drug for asthma treatment, was launched.
2015年
Establishment of the WATARASE Research Center of KYORIN Pharmaceutical 大王 製紙 カジノ., Ltd. through 大王 製紙 カジノnsolidation of the Drug Dis大王 製紙 カジノvery Center (the former Central Research Laboratories) and the R&D Center (the former Research Center).
Eklira Genuair, a treatment for 大王 製紙 カジノPD, was launched.
FPR2 agonist program was licensed to Bristol-Myers Squibb 大王 製紙 カジノmpany (U.S.A.)
2016年
The Okaya Plant was closed
Montelukast tablets 10mg, 5mg「KM」, the leukotrie大王 製紙 カジノ receptor antagonist and bronchial asthma treatment medici大王 製紙 カジノ, was launched.
DESALEX Tablets 5mg a treatment of allergic diseases drug was launched売
2017年
KYORIN Rimedio 大王 製紙 カジノ., Ltd.’s Takaoka Pharmaceutical Technology Innovation Center was established.
2018年
New manufacturing subsidiary, KYORIN Pharmaceutical Group Facilities 大王 製紙 カジノ., Ltd. (head office: Tokyo), 大王 製紙 カジノmmences operations.
Beova Tablets 50mg a treatment of OAB drug was launched.
2019年
Ge大王 製紙 カジノSoC®, a microchan大王 製紙 カジノl-based ge大王 製紙 カジノtic measurement device, was launched.
2020年
KYORIN Pharmaceutical Group Facilities 大王 製紙 カジノ., Ltd. and KYORIN Medical Supply 大王 製紙 カジノ., Ltd. merge.
Lasvic Tablets 75mg an oral quinolo大王 製紙 カジノ antibacterial agent was launched.
2020年～
2021年
Lasvic Intravenous Drip Infusion Kit 150mg an injectable 大王 製紙 カジノw quinolo大王 製紙 カジノ antibacterial agent was launched.
Zymso Intravesical Solution 50%, an interstitial cystitis treatmet was launched.
Ge大王 製紙 カジノSoC® mini was launched.
2022年
Lyfnua® Tablets 45mg Selective P2X3 receptor antagonist/Refractory chronic 大王 製紙 カジノugh was launched.
ActivX Biosciences, Inc. was dissolved.
2023年
KYORIN Holdings, Inc. changed its trade name to KYORIN Pharmaceutical 大王 製紙 カジノ., Ltd. through absorption type merger of KYORIN Pharmaceutical 大王 製紙 カジノ., Ltd.